▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #968 by analyst upside · 2026-11-13
ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Market Cap $7B · P/E 0x
ANALYST PRICE TARGET
+126.3%
implied upside to consensus target
Current Price $47.15
Consensus Target $106.71
Bull Target $126.0
Bear Target $74.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
9
Hold
1
Sell
0
52-Week Low $37.06
52-Week High $95.49
YTD Return -30.4%
FUNDAMENTALS
Market Cap $7B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-2.28
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $669M
Profit Margin -47.8%
52-WEEK RANGE
52-Week Low $37.06
52-Week High $95.49
Current Price $47.15
Bear Target $74.0
Bull Target $126.0
● Now $47.15 ● Target $106.71
TRADING DATA
Avg Volume 1.9M
YTD Return -30.4%
Analyst Count 14
Consensus Buy
Upside to Target +126.3%
Last Updated 2026-11-13

ANALYST SUMMARY

Arrowhead Pharmaceuticals, Inc. (ARWR) is currently trading at $47.15 with a Wall Street consensus price target of $106.71, implying potential upside of 126.3% over the next 12 months. 14 analysts currently cover ARWR, with a consensus rating of Buy - 93% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $126.0, while the most cautious has a target of $74.0.

ARWR operates in the Healthcare sector with a market capitalisation of $7B. The stock is down 30.4% year-to-date and is currently trading near the lower end of its 52-week range of $37.06 – $95.49.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for ARWR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital - Reiterated
Buy → Buy 2026-10-15 33% win rate (6 calls)
HC Wainwright & Co. reit
Buy → Buy 2026-10-15 31% win rate (48 calls)
Citigroup ● Initiated
Buy 2026-09-08 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-09-01 31% win rate (48 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-31 33% win rate (6 calls)
RBC Capital reit
Outperform → Outperform 2026-08-31 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-08-06 31% win rate (48 calls)
B. Riley Securities - Reiterated
Buy → Buy 2026-07-30 17% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
51
out of 100
Coverage depth
21/30
Consensus clarity
8/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →